IN2014DN11181A - - Google Patents

Info

Publication number
IN2014DN11181A
IN2014DN11181A IN11181DEN2014A IN2014DN11181A IN 2014DN11181 A IN2014DN11181 A IN 2014DN11181A IN 11181DEN2014 A IN11181DEN2014 A IN 11181DEN2014A IN 2014DN11181 A IN2014DN11181 A IN 2014DN11181A
Authority
IN
India
Prior art keywords
apc
treat
individual
methods
effective amount
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher John Jackson
Meilang Xue
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902874A external-priority patent/AU2012902874A0/en
Application filed by Univ Sydney filed Critical Univ Sydney
Publication of IN2014DN11181A publication Critical patent/IN2014DN11181A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN11181DEN2014 2012-07-04 2013-07-04 IN2014DN11181A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (1)

Publication Number Publication Date
IN2014DN11181A true IN2014DN11181A (enExample) 2015-10-02

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11181DEN2014 IN2014DN11181A (enExample) 2012-07-04 2013-07-04

Country Status (12)

Country Link
US (3) US20150150954A1 (enExample)
EP (1) EP2869833B1 (enExample)
JP (1) JP6273272B2 (enExample)
KR (1) KR102068010B1 (enExample)
CN (1) CN104394883B (enExample)
AU (1) AU2013286812B2 (enExample)
BR (1) BR112015000051A2 (enExample)
CA (1) CA2877745C (enExample)
ES (1) ES2676422T3 (enExample)
IN (1) IN2014DN11181A (enExample)
RU (1) RU2662564C2 (enExample)
WO (1) WO2014005183A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
EP3137102B1 (en) * 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) * 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
CN108779115B (zh) 2016-10-14 2021-02-26 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
US20210268062A1 (en) * 2018-06-28 2021-09-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
US20220079990A1 (en) * 2018-12-26 2022-03-17 Direct Biologics Llc Methods and compositions for treating skin and hair disorders
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
EP3999083A4 (en) 2019-07-18 2023-07-26 Direct Biologics LLC Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
AU2467395A (en) 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
AU2001232799A1 (en) 2000-02-11 2001-08-20 Eli Lilly And Company Protein c derivatives
ES2242740T3 (es) * 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
AU1038802A (en) 2000-10-18 2002-04-29 Maxygen Aps Protein c or activated protein c-like molecules
ES2384099T3 (es) * 2001-06-13 2012-06-29 The University Of Sydney Proteína C para cicatrización de heridas
WO2004041296A2 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
EP1477166B1 (de) 2003-04-28 2006-08-23 Biofrontera Bioscience GmbH Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2005007820A2 (en) 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
CN101262880A (zh) 2005-06-24 2008-09-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
AU2006278504B2 (en) * 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
WO2010113146A1 (en) * 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
EP3137102B1 (en) * 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) * 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
US20210268062A1 (en) * 2018-06-28 2021-09-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Also Published As

Publication number Publication date
EP2869833A4 (en) 2015-11-18
US20200276281A1 (en) 2020-09-03
JP6273272B2 (ja) 2018-01-31
EP2869833A1 (en) 2015-05-13
CN104394883B (zh) 2017-05-31
US11617785B2 (en) 2023-04-04
RU2662564C2 (ru) 2018-07-26
US20150150954A1 (en) 2015-06-04
JP2015521632A (ja) 2015-07-30
KR20150036351A (ko) 2015-04-07
BR112015000051A2 (pt) 2017-06-27
CA2877745C (en) 2021-11-30
EP2869833B1 (en) 2018-04-04
WO2014005183A1 (en) 2014-01-09
AU2013286812A1 (en) 2015-01-22
CA2877745A1 (en) 2014-01-09
HK1204573A1 (en) 2015-11-27
RU2015103510A (ru) 2016-08-27
AU2013286812B2 (en) 2017-04-20
US20170080062A1 (en) 2017-03-23
KR102068010B1 (ko) 2020-01-20
ES2676422T3 (es) 2018-07-19
CN104394883A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
IN2014DN11181A (enExample)
PH12018500452A1 (en) Novel modulators and methods of use
PH12015500525A1 (en) Formulations of enzalutamide
MY167585A (en) Disposable diaper
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
UA110813C2 (uk) Лікування ліподистрофії
BR112014017799A8 (pt) Compostos inibidores de metaloenzima
MY165759A (en) Pull-on diaper
IN2014DN00288A (enExample)
IN2014DN00286A (enExample)
IN2014MN00093A (enExample)
IN2014MN01378A (enExample)
IN2014DN08481A (enExample)
MY168032A (en) Warm-Cool Beauty Treatment Device
LT2890793T (lt) Lakių dienų gamyba, fermentiniu būdu (ec 4.2.1.127) dehidratuojant lengvuosius alkenolius
IN2014DN06792A (enExample)
UY34652A (es) Anticuerpos humanos frente a toxinas de clostridium difficile
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
MY166103A (en) Disposable diaper
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MY167652A (en) Disposable diaper
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
GEP201706626B (en) Synthesis of (s)-nifuratel
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors